These data suggest that PARK2 mutations cause mitochondrial dysfunction even in non-neuronal cells confirming that skin fibroblasts from PARK2 mutant patients may be a suitable system to gain further details on cellular dysfunction underlying PD and possibly to test new therapeutic approaches. This evidence concerns the gene PRKN and Parkinson disease.